Lupin Launches Generic Cancer Drug in US - Doxorubicin Hydrochloride Liposome Injection

New Delhi, Aug 29 (PTI) Drug firm Lupin on Thursday said it has launched a generic cancer treatment drug in the US market.

The company said it has launched Doxorubicin Hydrochloride Liposome Injection single-dose vials in the US.

The Mumbai-based drug maker introduced the product after its alliance partner, ForDoz Pharma Corporation, USA (ForDoz) received approval from the USFDA, Lupin said in a statement.

The company's product is a generic version of Baxter Healthcare Corporation's Doxil which is indicated for the treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi's Sarcoma, and multiple myeloma.

As per the Iqvia MATdata, Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales of USD 40.9 million in the US.

Lupin shares on Thursday ended 0.21 per cent at Rs 2,195.20 apiece on the BSE.